Avidity Biosciences (RNA) PT Raised to $45 at BofA Securities

Avidity Biosciences (RNA) Announces Proposed $300M Share Offering

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of common stock. All of the shares to be sold in the offering are to be sold by Avidity. There can be no... More

Avidity Biosciences (RNA) Announces Data from Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in FSHD

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced positive initial AOC 1020 data from the Phase 1/2 FORTITUDE trial demonstrating unprecedented and consistent reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy (FSHD). Avidity plans to accelerate initiation of registrational cohorts in the FORTITUDE study. Avidity also announced delpacibart braxlosiran as the approved international... More

Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)

Wells Fargo analyst Yanan Zhu reiterated an Overweight rating and $50.00 price target on Avidity Biosciences (NASDAQ: RNA).

The analyst comments "Highlighting relentless disease progression and unmet needs. Our KOL noted that her FSHD patients invariably decline over time, with all patients... More